Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review

References

• WHO position paper on hepatitis A vaccines - June 2012. Wkly Epidemiol Rec 2012; 87:261-76; PMID:22905367
   PubMedGoogle Scholar
• Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr 2011; 10:57; PMID:22008459; http://dx.doi.org/10.1186/1476-072X-10-57
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control Prevention. Chapter 3 infectious diseases related to travel - Hepatitis A. In: Nelson NP, Murphy TV, eds. CDC Health Information for International Travel 2016. New York: Oxford University Press, 2016.
   Google Scholar
• Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 2000; 18 Suppl 1:S71-4; PMID:10683554; http://dx.doi.org/10.1016/S0264-410X(99)00470-3
   PubMed Web of Science ®Google Scholar
• Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45:1-30; PMID:9005304
   PubMedGoogle Scholar
• Burroughs AK, Westaby D. Chapter 7 - Liver, biliary tract and pancreatic disease. In: Kumar P, Clark M, eds. Clinical Medicine London: Elsevier Saunders, 2005:362-4.
   Google Scholar
• Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 2005; 34:600-9; PMID:15831565; http://dx.doi.org/10.1093/ije/dyi062
   PubMed Web of Science ®Google Scholar
• Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004; 132:1005-22; PMID:15635957; http://dx.doi.org/10.1017/S0950268804002857
   PubMed Web of Science ®Google Scholar
• Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, Sweet K, Phan Q, Cronquist A, Khudyakov Y, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005–2007. Arch Intern Med 2010; 170:1811-8; PMID:21059974; http://dx.doi.org/10.1001/archinternmed.2010.401
   PubMedGoogle Scholar
• Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005; 4:459-71; PMID:16117704; http://dx.doi.org/10.1586/14760584.4.4.459
   PubMed Web of Science ®Google Scholar
• Shouval D. The immunological basis for immunization series. Immunization vaccines and biologicals Geneva: World Health Organization, 2011:1-39.
   Google Scholar
• Van Damme P, Van Herck K. Effect of hepatitis A vaccination programs. JAMA 2005; 294:246-8; PMID:16014600; http://dx.doi.org/10.1001/jama.294.2.246
   PubMed Web of Science ®Google Scholar
• Wu JY, Liu Y, Chen JT, Xia M, Zhang XM. Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive(R). Hum Vaccin Immunother 2012; 8:1836-44; PMID:23032165; http://dx.doi.org/10.4161/hv.21909
   PubMed Web of Science ®Google Scholar
• Irving GJ, Holden J, Yang R, Pope D. Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database Syst Rev 2012; 7:CD009051; PMID:22786522; http://dx.doi.org/10.1002/14651858
   PubMedGoogle Scholar
• Franco E, Giambi C, Ialacci R, Maurici M. Prevention of hepatitis A by vaccination. Expert Opin Biol Ther 2003; 3:965-74; PMID:12943455; http://dx.doi.org/10.1517/14712598.3.6.965
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Gluck R, Herzog C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15:1209-13; PMID:9286045; http://dx.doi.org/10.1016/S0264-410X(97)00015-7
   PubMed Web of Science ®Google Scholar
• Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328-34; PMID:8158817; http://dx.doi.org/10.1001/jama.1994.03510410040030
   PubMed Web of Science ®Google Scholar
• Lopez EL, Del Carmen Xifro M, Torrado LE, De Rosa MF, Gomez R, Dumas R, Wood SC, Contrini MM. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 2001; 20:48-52; PMID:11176566; http://dx.doi.org/10.1097/00006454-200101000-00009
   PubMed Web of Science ®Google Scholar
• Ren YH, Chen JT, Wu WT, Gong XJ, Zhang YC, Xue WH, Ren YF, Han LJ, Kang WX, Li SP, et al. [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children]. Zhonghua Liu Xing Bing Xue Za Zhi 2003; 24:1013-5; PMID:14687502
   PubMedGoogle Scholar
• Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453-7; PMID:1320740; http://dx.doi.org/10.1056/NEJM199208133270702
   PubMed Web of Science ®Google Scholar
• Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63:1-7; PMID:11130881; http://dx.doi.org/10.1002/1096-9071(200101)63:1%3c1::AID-JMV1000%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 2014; 32:1507-13; PMID:24508042; http://dx.doi.org/10.1016/j.vaccine.2013.10.088
   PubMed Web of Science ®Google Scholar
• Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28:6653-7; PMID:20723630; http://dx.doi.org/10.1016/j.vaccine.2010.08.037
   PubMed Web of Science ®Google Scholar
• Vizzotti C, Gonzalez J, Gentile A, Rearte A, Ramonet M, Canero-Velasco MC, Pérez Carrega ME, Urueña A, Diosque M. Impact of the Single-dose Immunization Strategy Against Hepatitis A in Argentina. Pediatr Infect Dis J 2014; 33:84-8; PMID:24352191; http://dx.doi.org/10.1097/INF.0000000000000042
   PubMed Web of Science ®Google Scholar
• Gouvernement du Québec. Programme québécois d'immunisation. Portail santé mieux-être 15 October 2015; Available from: http://sante.gouv.qc.ca/programmes-et-mesures-daide/programme-quebecois-d-immunisation/ [Accessed on 17 November 2015].
   Google Scholar
• Domínguez A, Oviedo M, Carmona G, Jansá J, Borrás E, Salleras L, Plasència A. Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain. Journal of viral hepatitis 2008; 15:51-6; http://dx.doi.org/10.1111/j.1365-2893.2008.01030.x
   PubMed Web of Science ®Google Scholar
• Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines 2004; 3:249-67; PMID:15176942; http://dx.doi.org/10.1586/14760584.3.3.249
   Google Scholar
• Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294:202-10; PMID:16014594; http://dx.doi.org/10.1001/jama.294.2.202
   PubMed Web of Science ®Google Scholar
• Ministry of Health - Kingdom of Bahrain. Recommended Immunization Schedule for the Expanded Program on Immunization, Bahrain. Available from: http://www.moh.gov.bh/en/healthinformation/Immunizations.aspx?print=true [Accessed on 16 January 2015].
   Google Scholar
• Ministério da Saúde - Brasil. SUS passa a oferecer vacina contra hepatite A para crianças. Blog da Saúde July 29, 2014; Available from: http://www.blog.saude.gov.br/index.php/570-destaques/34211-sus-passa-a-oferecer-vacina-contra-hepatite-a-para-criancas [Accessed on 9 June 2015].
   Google Scholar
• Cui F, Hadler SC, Zheng H, Wang F, Zhenhua W, Yuansheng H, Gong X, Chen Y, Liang X. Hepatitis A surveillance and vaccine use in China from 1990 through 2007. J Epidemiol 2009; 19:189-95; PMID:19561383; http://dx.doi.org/10.2188/jea.JE20080087
   PubMed Web of Science ®Google Scholar
• Viral Hepatitis Prevention Board. Prevention and control of viral hepatitis in Greece: Lessons learnt and the way forward. Viral Hepatitis 2008; 16.
   Google Scholar
• Kyrka A, Tragiannidis A, Cassimos D, Pantelaki K, Tzoufi M, Mavrokosta M, Pedeli X, Athanassiadou F, Hatzimichael A, Konstantopoulos A, et al. Seroepidemiology of hepatitis A among Greek children indicates that the virus is still prevalent: Implications for universal vaccination. Journal of medical virology 2009; 81:582-7; PMID:19235841; http://dx.doi.org/10.1002/jmv.21434
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud - Panama. Esquema Nacional de Vacunación. 2013; Available from: http://www.minsa.gob.pa/sites/default/files/programas/esquema_de_vacunacion_revisado_marzo_2013.pdf [Accessed on 16 January 2015].
   Google Scholar
• Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294:194-201; PMID:16014593; http://dx.doi.org/10.1001/jama.294.2.194
   PubMed Web of Science ®Google Scholar
• Romero C, Perdomo V, Chamorro F, Assandri E, Pírez MC, Montano A. Prevención de hepatitis A mediante vacunación en Uruguay (2005–2010). Rev Méd Urug 2012; 28:115-22
   Google Scholar
• Fisenka EG, Germanovich FA, Glinskaya IN, Lyabis OI, Rasuli AM. Effectiveness of universal hepatitis A immunization of children in Minsk City, Belarus: four-year follow-up. J Viral Hepat 2008; 15 Suppl 2:57-61; PMID:18837836; http://dx.doi.org/10.1111/j.1365-2893.2008.01031.x
   PubMed Web of Science ®Google Scholar
• Martinelli D, Bitetto I, Tafuri S, Lopalco PL, Mininni RM, Prato R. Control of hepatitis A by universal vaccination of children and adolescents: an achieved goal or a deferred appointment? Vaccine 2010; 28:6783-8; PMID:20688041; http://dx.doi.org/10.1016/j.vaccine.2010.07.069
   PubMed Web of Science ®Google Scholar
• Martinez A, Broner S, Sala MR, Manzanares-Laya S, Godoy P, Planas C, Minguell S, Torner N, Jané M, Domínguez A, et al. Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program. Hum Vaccin Immunother 2014; 11; PMID:25483535; PMCID:PMC4514321; http://dx.doi.org/10.4161/hv.35861
   Web of Science ®Google Scholar
• Mellou K, Sideroglou T, Papaevangelou V, Katsiaflaka A, Bitsolas N, Verykouki E, Triantafillou E, Baka A, Georgakopoulou T, Hadjichristodoulou C. Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks. PLoS One 2015; 10:e0116939; PMID:25590132; http://dx.doi.org/10.1371/journal.pone.0116939
   PubMed Web of Science ®Google Scholar
• Belmaker I, Dukhan L, Yosef Y, Leventhal A, Dagan R. Elimination of hepatitis a infection outbreaks in day care and school settings in southern Israel after introduction of the national universal toddler hepatitis a immunization program. Pediatr Infect Dis J 2007; 26:36-40; PMID:17195703; http://dx.doi.org/10.1097/01.inf.0000247105.45185.13
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Weinbaum C, McCauley M, Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996–2004. Vaccine 2007; 25:3581-7; PMID:17306908; http://dx.doi.org/10.1016/j.vaccine.2007.01.081
   PubMed Web of Science ®Google Scholar
• Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 2008; 197:1282-8; PMID:18422440; http://dx.doi.org/10.1086/586899
   PubMed Web of Science ®Google Scholar
• Collier MG, Tong X, Xu F. Hepatitis a hospitalizations in the United States, 2002 – 2011. Hepatology 2015; 61:481-5; PMID:25266085; http://dx.doi.org/10.1002/hep.27537
   PubMed Web of Science ®Google Scholar
• Papaevangelou V, Alexopoulou Z, Hadjichristodoulou C, Kourlamba G, Katsioulis A, Theodoridou K, Spoulou V, Theodoridou M. Time trends in pediatric hospitalizations for hepatitis A in Greece (1999–2013): Assessment of the impact of universal infant immunization in 2008. Hum Vaccin Immunother 2016; 12:1852-6; PMID:27141813; PMCID:PMC4964822; http://dx.doi.org/10.1080/21645515.2016.1151589
   PubMed Web of Science ®Google Scholar
• Chodick G, Green MS, Heymann AD, Rosenmann L, Shalev V. The shifting epidemiology of hepatitis A following routine childhood immunization program in Israel. Prev Med 2007; 45:386-91; PMID:17599401; http://dx.doi.org/10.1016/j.ypmed.2007.05.011
   PubMed Web of Science ®Google Scholar
• Levine H, Kopel E, Anis E, Givon-Lavi N, Dagan R. The impact of a national routine immunisation programme initiated in 1999 on Hepatitis A incidence in Israel, 1993 to 2012. Euro Surveill 2015; 20:3-10; PMID:25719962; http://dx.doi.org/10.2807/1560-7917.ES2015.20.7.21040
   PubMedGoogle Scholar
• Singleton RJ, Hess S, Bulkow LR, Castrodale L, Provo G, McMahon BJ. Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska. Vaccine 2010; 28:6298-304; PMID:20637769; http://dx.doi.org/10.1016/j.vaccine.2010.06.113
   PubMed Web of Science ®Google Scholar
• Erhart LM, Ernst KC. The changing epidemiology of hepatitis A in Arizona following intensive immunization programs (1988–2007). Vaccine 2012; 30:6103-10; PMID:22835739; http://dx.doi.org/10.1016/j.vaccine.2012.07.029
   PubMed Web of Science ®Google Scholar
• Estripeaut D, Contreras R, Tinajeros O, Castrejon MM, Shafi F, Ortega-Barria E, DeAntonio R. Impact of Hepatitis A vaccination with a two-dose schedule in Panama: Results of epidemiological surveillance and time trend analysis. Vaccine 2015; 33:3200-7; PMID:25981490; http://dx.doi.org/10.1016/j.vaccine.2015.04.100
   PubMed Web of Science ®Google Scholar
• Ly KN, Klevens RM. Trends in Disease and Complications of Hepatitis A Virus Infection in the United States, 1999–2011: A New Concern for Adults. J Infect Dis 2015; 212:176-82; PMID:25637352; http://dx.doi.org/10.1093/infdis/jiu834
   PubMed Web of Science ®Google Scholar
• Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, Byrd KK, Sharapov UM, Hennessy TW, McMahon BJ. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis 2013; 207:493-6; PMID:23204169; http://dx.doi.org/10.1093/infdis/jis710
   PubMed Web of Science ®Google Scholar
• Espul C, Benedetti L, Linares M, Cuello H, Rasuli A. Five-year follow-up of immune response after one or two doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. J Viral Hepat 2014; PMID:25262590; http://dx.doi.org/10.1111/jvh.12317
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shapiro CN, Sabin K, Labonte K, Darling K, Culver D, Bell BP, Margolis HS. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003; 22:354-9; PMID:12690277; http://dx.doi.org/10.1097/01.inf.0000059446.52063.b9
   PubMed Web of Science ®Google Scholar
• Spradling PR, Bulkow LR, Negus SE, Homan C, Bruce MG, McMahon BJ. Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up. Hepatology 2016; 63:703-11; PMID:26637987; http://dx.doi.org/10.1002/hep.28375
   PubMed Web of Science ®Google Scholar
• Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine 2012; 31:3-11; PMID:22609026; http://dx.doi.org/10.1016/j.vaccine.2012.04.104
   PubMed Web of Science ®Google Scholar
• Dagan R, Ashkenazi S, Livni G, Go O, Bagchi P, Sarnecki M. Long-term serologic follow-up of children vaccinated with a pediatric formulation of virosomal hepatitis a vaccine administered with routine childhood vaccines at 12–15 months of age. Pediatr Infect Dis J 2016; 35:e220–8; PMID:27093164; http://dx.doi.org/10.1097/INF.0000000000001176
   PubMedGoogle Scholar
• Raczniak GA, Thomas TK, Bulkow LR, Negus SE, Zanis CL, Bruce MG, Spradling PR, Teshale EH, McMahon BJ. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine 2013; 31:2152-5; PMID:23470239; http://dx.doi.org/10.1016/j.vaccine.2013.02.048
   PubMed Web of Science ®Google Scholar
• Yu C, Song Y, Qi Y, Li C, Jiang Z, Li C, Zhang W, Wang L, Xia J. Comparison of Immunogenicity and Persistence between Inactivated Hepatitis A Vaccine Healive(R) and Havrix(R) among Children: A 5-Year Follow-up Study. Hum Vaccin Immunother 2016; 12(10):2595-602; PMID:27385349; http://dx.doi.org/10.1080/21645515.2016.1197450
   Web of Science ®Google Scholar
• Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, Fleenor M, Ryder PL, Margolis HS. The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies. J Infect Dis 1998; 178:1579-84; PMID:9815207; http://dx.doi.org/10.1086/314518
   PubMed Web of Science ®Google Scholar
• Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med 1980; 302:1222-7; PMID:6245363; http://dx.doi.org/10.1056/NEJM198005293022203
   PubMed Web of Science ®Google Scholar
• Smith PF, Grabau JC, Werzberger A, Gunn RA, Rolka HR, Kondracki SF, Gallo RJ, Morse DL. The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect 1997; 118:243-52; PMID:9207735; http://dx.doi.org/10.1017/S0950268897007462
   PubMed Web of Science ®Google Scholar
• Staes CJ, Schlenker TL, Risk I, Cannon KG, Harris H, Pavia AT, Shapiro CN, Bell BP. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 2000; 106:E54; PMID:11015549; http://dx.doi.org/10.1542/peds.106.4.e54
   PubMed Web of Science ®Google Scholar
• Xu Z-Y, Wang X-Y. Live attenuated hepatitis A vaccines developed in China. Hum Vaccin Immunother 2014; 10:659-66; PMID:24280971; http://dx.doi.org/10.4161/hv.27124
   PubMed Web of Science ®Google Scholar
• Cui F, Hadler SC, Zheng H, Wang F, Zhenhua W, Yuansheng H, Gong X, Chen Y, Liang X. Hepatitis A surveillance and vaccine use in China from 1990 through 2007. J Epidemiol 2009; 19:189-95; PMID:19561383; http://dx.doi.org/10.2188/jea.JE20080087
   PubMed Web of Science ®Google Scholar
• Jacobsen KH. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. World Health Organization 2009; 1-413. Available from: http://whqlibdoc.who.int/hq/2010/WHO_IVB_10.01_eng.pdf [Accessed on 24 October 2015]
   Google Scholar
• Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol 2012; 4:68-73; PMID:22489258; http://dx.doi.org/10.4254/wjh.v4.i3.68
   PubMedGoogle Scholar
• Chodick G, Heymann AD, Ashkenazi S, Kokia E, Shalev V. Long-term trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization program. J Viral Hepat 2008; 15 Suppl 2:62-5; PMID:18837837; http://dx.doi.org/10.1111/j.1365-2893.2008.01032.x
   PubMed Web of Science ®Google Scholar
• Collier MG, Khudyakov YE, Selvage D, Adams-Cameron M, Epson E, Cronquist A, Jervis RH, Lamba K, Kimura AC, Sowadsky R, et al. Outbreak of hepatitis A in the USA associated with frozen pomegranate arils imported from Turkey: an epidemiological case study. The Lancet Infectious Diseases 2014; 14:976-81; PMID:25195178; http://dx.doi.org/10.1016/S1473-3099(14)70883-7
   PubMed Web of Science ®Google Scholar
• Severi E, Verhoef L, Thornton L, Guzman-Herrador BR, Faber M, Sundqvist L, Rimhanen-Finne R, Roque-Afonso AM, Ngui SL, Allerberger F, et al. Large and prolonged food-borne multistate hepatitis A outbreak in Europe associated with consumption of frozen berries, 2013 to 2014. Euro Surveill 2015; 20:21192; PMID:26227370; http://dx.doi.org/10.2807/1560-7917.ES2015.20.29.21192
   Google Scholar
• Sharapov UM, Bulkow LR, Negus SE, Spradling PR, Homan C, Drobeniuc J, Bruce M, Kamili S, Hu DJ, McMahon BJ. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology 2012; 56:516-22; PMID:22371069; http://dx.doi.org/10.1002/hep.25687
   PubMed Web of Science ®Google Scholar
• Lopez EL, Contrini MM, Mistchenko A, Kieffer A, Baggaley RF, Di Tanna GL, Desai K, Rasuli A, Armoni J. Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children. Pediatr Infect Dis J 2015; 34:417-25; PMID:25764099; http://dx.doi.org/10.1097/INF.0000000000000605
   PubMed Web of Science ®Google Scholar
• Bian GL, Ma R, Dong HJ, Ni HX, Hu FJ, Chen YR, Chen JQ, Zhou SY, Lin YX, Xu GZ. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 2010; 28:4798-801; PMID:20471440; http://dx.doi.org/10.1016/j.vaccine.2010.04.096
   PubMed Web of Science ®Google Scholar
• Van Herck K, Hens A, De Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine. Pediatr Infect Dis J 2015; 34:e85–91; PMID:25389920; http://dx.doi.org/10.1097/INF.0000000000000616
   PubMedGoogle Scholar
• Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-23; PMID:16708058
   PubMedGoogle Scholar
• Hatz C, Van der Ploeg R, Beck BR, Frösner G, Hunt M, Herzog C. Successful memory response following a booster dose with a virosome-formulated hepatitis A vaccine delayed up to 11 years. Clin Vaccine Immunol 2011; 18:885-7; PMID:21411599; http://dx.doi.org/10.1128/CVI.00358-10
   PubMed Web of Science ®Google Scholar
• Iwarson S, Lindh M, Widerstrom L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004; 11:120-1; PMID:15109480; http://dx.doi.org/10.2310/7060.2004.17079
   PubMed Web of Science ®Google Scholar
• Landry P, Tremblay S, Darioli R, Genton B. Inactivated hepatitis A vaccine booster given≥ 24 months after the primary dose. Vaccine 2000; 19:399-402; PMID:11027799; http://dx.doi.org/10.1016/S0264-410X(00)00188-2
   PubMed Web of Science ®Google Scholar